The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive, HER2-negative breast cancer. It shows better progression-free survival (PFS) for patients, as reported in the New England Journal of Medicine. Let’s explore the trial’s key findings. Advertisement What is the Camizestrant SERENA-6 Trial? The SERENA-6 … Continue reading Camizestrant SERENA-6 Trial: ASCO 2025 Insights